Digital-output cardiotachometer measures rapid changes in heartbeat rate

Cardiotachometer circuits produce an output voltage proportional to the heartbeat rate on a beat-by-beat basis. This is less complex and less costly than the digital cardiotachometers

Inexpensive, stable circuit measures heart rate

Inexpensive transistorized circuit provides reliable analog indications of heart rate in response to preamplified electrocardiograph signal applied to its input

Blood pressure measuring system for separating and separately recording dc signal and an ac signal Patent

Blood pressure measuring system for separately recording dc and ac pressure signals of Korotkoff sound

Biomedical recording system

System collects medical data directly from patients and permanently records and displays several parameters - electrocardiograph, electroencephalograph, heart rate, respiration rate, auscultatory blood pressure, leg circumference changes, body temperature, and time. Components and operation of the system are described

Space shuttle main engine hardware simulation

The Huntsville Simulation Laboratory (HSL) provides a simulation facility to test and verify the space shuttle main engine (SSME) avionics and software system using a maximum complement of flight type hardware. The HSL permits evaluations and analyses of the SSME avionics hardware, software, control system, and mathematical models. The laboratory has performed a wide spectrum of tests and verified operational procedures to ensure system component compatibility under all operating conditions. It is a test bed for integration of hardware/software/hydraulics. The HSL is and has been an invaluable tool in the design and development of the SSME

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.

A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m(2)/day or 150 mg/m(2)/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m(2)/day or 125 mg/m(2)/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity